| Names | |
|---|---|
| IUPAC name
N-[5-[4-[(4-chloro-3-fluorophenyl)methyl]-6-methoxy-3,5-dioxo-1,2,4-triazin-2-yl]-2-fluorophenyl]acetamide | |
| Identifiers | |
3D model (JSmol) |
|
PubChem CID |
|
| |
| |
| Properties | |
| C19H15ClF2N4O4 | |
| Molar mass | 436.80 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
ADX-71441 is a GABAB receptor positive allosteric modulator currently being investigated as a potential treatment for anxiety, epilepsy, pain and other conditions.
ADX-71441 has been shown to reduce alcohol consumption. This result was observed in both alcohol dependent and non-dependent animals.
There were also trials about nicotine addiction, which showed positive results: ADX-71441 was able to decrease some withdrawal symptoms of nicotine withdrawal.
This compound has also been shown to reduce anxiety in people with PTSD.
Experiments have shown that this compound was able to decrease hypersensitivity to pain in mice, Guinea pigs and rats.
ADX-71441 has been shown to have less tolerance and side effects than direct GABAB agonists, such as baclofen.